Evin Gulbahce, MD, MSCI

Professor, University of Utah School of Medicine

Specialties

• Breast pathology
• FISH

Education

• Medical Degree—Hacettepe University School of Medicine
• Residency—Anatomic and Clinical Pathology, University of Minnesota
• Fellowship—Surgical Pathology, University of Minnesota
• MS Clinical Investigation—University of Utah

Certification/Affiliations

• American Board of Pathology

Research Interests

• Breast cancer risk factors, specifically for basal-like and triple negative breast cancers
• HER2 testing

Awards

• Clinical Excellence, Department of Pathology, University of Utah
• Outstanding Teaching Award, Department of Pathology, University of Utah

Recent Publications

• Mahlow J, et al. Presence of internal controls in hormone receptor testing is dependent on the breast cancer subtype and should be considered in ASCO/CAP guideline update revision. Appl Immunohistochem Mol Morphol. 2020. [Online ahead of print]
• Gulbahce HE, et al. Interference of tissue-marking dyes with fluorescent in situ hybridization (FISH) assays. Arch Pathol Lab Med. 2019;143(11):1299.
• Lin L, et al. American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 focused update of breast cancer HER2 FISH testing guidelines: results from a national reference laboratory. Am J Clin Pathol.  2019;152(4):479–85.
• Schneider F, et al. The FDA -approved breast cancer HER2 evaluation kit (HercepTest, Dako) may miss aome HER2-positive breast cancers. Am J Clin Pathol.  2019;151(5):504-510.
• Gulbahce HE, et al. Differences in molecular features of triple negative breast cancer based on age at diagnosis. Cancer. 2018;124:4676–84.
• Gulbahce HE. Impact of 2013 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on HER2 fluorescent in situ hybridization (FISH) testing in breast cancers: experience from a national reference laboratory. Am J Clin Pathol. 2017; 148(4):308–13.
• Johnson ED, et al.  Primary cystic pleuropulmonary synovial sarcoma presenting as recurrent pneumothorax. Case Rep Onco. 2017;10(2):660–5.
• Stewart RL, et al. HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features. Mod Pathol. 2017;30(11):1561–6.
• Ling H, et al. RAI1 alternate probe identifies additional breast cancer cases as amplified following equivocal HER2 FISH testing: experience from a national reference laboratory. Arch of Pathol Lab Med. 2017;141(2):274–8.
• Johnson E, et al. Malignant phyllodes tumor presenting in bone, brain, lungs, and lymph nodes. Case Rep Onco. 2016;9:861–8.
• Geiersbach K, et al. Genomic copy number analysis of HER2 equivocal breast cancers. Am J Clin Pathol. 2016;146(4):439–47.
• Willmore-Payne C, et al. Inconsistent results with different secondary reflex assays in resolving HER2 status. AM J Clin Pathol. 2016;146(5):618–26. 
• Gulbahce HE, et al. HER2 immunohistochemistry guided targeted FISH analysis does not help identify intratumoral heterogeneity in breast cancer. Arch Pathol Lab Med. 2016;140(8):741.
• Gulbahce HE, et al. Quantification of estrogen receptor expression in normal breast tissue in postmenopausal women with breast cancer and association with tumor subtypes. Appl Immunohistochem Mol Morphol. 2017;25(8):548–52.